{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-041285","form_type":"8-K/A","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2024-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.075629+00:00","generated_at":"2026-05-30T13:44:40.467086+00:00","sec_items":["3.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sigyn corrects prior error; debenture conversion adds 118,700 shares, 9.1% share increase","bullets":["Corrected prior error: sellers were not controlled by an executive officer.","$474,793 of convertible debentures converted at $4.00/share for 118,700 shares.","Shares issued with Rule 144 legend, exempt under Section 4(a)(2).","Outstanding common shares increased from 1,301,978 to 1,420,678."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-041285","json":"https://secwatch.observer/filing/0001493152-24-041285.json","markdown":"https://secwatch.observer/filing/0001493152-24-041285.md","text":"https://secwatch.observer/filing/0001493152-24-041285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224041285/0001493152-24-041285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224041285/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T13:44:40.467086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}